Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trade groups on bird flu

This article was originally published in The Tan Sheet

Executive Summary

"Marketers and retailers of dietary supplements are urged to refuse to stock or sell any products that are presented as preventing, treating or curing avian flu," a coalition of supplement industry trade groups announces in a joint advisory issued Nov. 18. The American Herbal Products Association, Consumer Healthcare Products Association, Council for Responsible Nutrition and National Nutritional Foods Association "encourag[e] consumers to use caution should they encounter products which claim to treat or prevent the avian flu" and note that "federal law and regulations do not allow any dietary supplement product" to make such claims. Although supplements can enhance general immune function, therapies for prevention or treatment of avian flu "should only be recommended by qualified healthcare professionals or public health authorities," the groups conclude...

You may also be interested in...



“Fowl” Play? FDA Warning Letters Target Avian Flu Supplement Marketers

Nine dietary supplement firms who received FDA warning letters for marketing their products as treatments for avian flu could face "far more serious enforcement activity" if they do not take "immediate corrective action," according to an industry lawyer

Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children

Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.

MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation

Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098855

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel